Chronic exercise confers neuroprotection in experimental autoimmune encephalomyelitis

Journal of Neuroscience Research

Volumn 93, Issue 5, 2015, Pages 697-706

  Pryor, William M ^a,b   Freeman, Kimberly G ^a   Larson, Rebecca D ^c   Edwards, Gaylen L ^a   White, Lesley J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Exercise; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuropathology; Neuroprotection

Indexed keywords

AEROBIC EXERCISE; ALPHA NERVE FIBER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL LOSS; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRAPYRAMIDAL SYSTEM; GRAY MATTER; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTERNEURON; KINESIOTHERAPY; LOCOMOTION; LONG TERM CARE; LUMBAR SPINAL CORD; MALE; MEDIAL LONGITUDINAL FASCICULUS; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROFILAMENT; NEUROPATHOLOGY; NEUROPROTECTION; NISSL SUBSTANCE; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL TRACT; RETICULOSPINAL TRACT; SEDENTARY LIFESTYLE; TECTOSPINAL TRACT; TREADMILL EXERCISE; WHITE MATTER; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISABILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERMEDIATE FILAMENT; METABOLISM; MOTONEURON; NONPARAMETRIC TEST; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SPINAL CORD;

FREUND ADJUVANT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ANIMALS; AXONS; DISABILITY EVALUATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXERCISE THERAPY; FREUND'S ADJUVANT; INTERMEDIATE FILAMENTS; MALE; MICE; MICE, INBRED C57BL; MOTOR NEURONS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX; SPINAL CORD; STATISTICS, NONPARAMETRIC;

EID: 84925438657     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23528     Document Type: Article

References (38)

1. Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R. 2005. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 102:19045-19050.
2. Arima Y, Harada M, Kamimura D, Park JH, Kawano F, Yull FE, Kawamoto T, Iwakura Y, Betz UA, Marquez G, Blackwell TS, Ohira Y, Hirano T, Murakami M. 2012. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148:447-457.
3. Bannerman PG, Hahn A, Ramirez S, Morley M, Bonnemann C, Yu S, Zhang GX, Rostami A, Pleasure D, 2005. Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice. Brain 128:1877-1886.
4. Beeton C, Garcia A, Chandy KG. 2007. Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis. J Vis Exp 224.
5. Berchtold NC, Chinn G, Chou M, Kesslak JP, Cotman CW. 2005. Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 133:853-861.
6. Brown DA, Sawchenko PE. 2007. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 502:236-260.
7. Carro E, Trejo JL, Busiguina S, Torres-Aleman I. 2001. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci 21:5678-5684.
8. Castellano V, White LJ. 2008. Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis. J Neurol Sci 269:85-91.
9. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J. 2011. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108:751-756.
10. Clark PJ, Bhattacharya TK, Miller DS, Rhodes JS. 2011. Induction of c-fos, Zif268, and arc from acute bouts of voluntary wheel running in new and preexisting adult mouse hippocampal granule neurons. Neuroscience 184:16-27.
11. De Stefano N, Narayanan S, Francis SJ, Smith S, Mortilla M, Tartaglia MC, Bartolozzi ML, Guidi L, Federico A, Arnold DL. 2002. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 59:1565-1571.
12. Dutta R, Trapp BD. 2011. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93:1-12.
13. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, van Horssen J, Lassmann H. 2012. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135:886-899.
14. Forte M, Gold BG, Marracci G, Chaudhary P, Basso E, Johnsen D, Yu X, Fowlkes J, Rahder M, Stem K, Bernardi P, Bourdette D. 2007. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A 104:7558-7563.
15. Gilgun-Sherki Y, Melamed E, Offen D. 2004. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261-268.
16. Goodin DS. 2008. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 71:S8-S13.
17. Grondard C, Biondi O, Armand AS, Lecolle S, Della Gaspera B, Pariset C, Li H, Gallien CL, Vidal PP, Chanoine C, Charbonnier F. 2005. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci 25:7615-7622.
18. Heesen C, Romberg A, Gold S, Schulz KH. 2006. Physical exercise in multiple sclerosis: supportive care or a putative disease-modifying treatment. Expert Rev Neurother 6:347-355.
19. Herrero-Herranz E, Pardo LA, Gold R, Linker RA. 2008. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 30:162-173.
20. Herz J, Zipp F, Siffrin V. 2010. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol 225:9-17.
21. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. 2009. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183:7169-7177.
22. Lassmann H. 2007. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 7:239-244.
23. Le Page C, Bourdoulous S, Beraud E, Couraud PO, Rieu M, Ferry A. 1996. Effect of physical exercise on adoptive experimental autoimmune encephalomyelitis in rats. Eur J Appl Physiol Occup Physiol 73:130-135.
24. Li S, Vana AC, Ribeiro R, Zhang Y. 2011. Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis. Neuroscience 184:107-119.
25. Linker RA, Sendtner M, Gold R. 2005. Mechanisms of axonal degeneration in EAE: lessons from CNTF and MHC I knockout mice. J Neurol Sci 233:167-172.
26. Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL. 1998. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 18:327-336.
27. Murakami M, Hirano T. 2011. A four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases. Front Immunol 2:22.
28. Ramagopalan SV, Byrnes JK, Orton SM, Dyment DA, Guimond C, Yee IM, Ebers GC, Sadovnick AD. 2010. Sex ratio of multiple sclerosis and clinical phenotype. Eur J Neurol 17:634-637.
29. Richards RG, Sampson FC, Beard SM, Tappenden P. 2002. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6:1-73.
30. Rossi S, Furlan R, De Chiara V, Musella A, Lo Giudice T, Mataluni G, Cavasinni F, Cantarella C, Bernardi G, Muzio L, Martorana A, Martino G, Centonze D. 2009. Exercise attenuates the clinical, synaptic, and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol Dis 36:51-59.
31. Rudick RA, Trapp BD. 2009. Gray-matter injury in multiple sclerosis. N Engl J Med 36:1505-1506.
32. Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G. 2003. Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil 84:1823-1830.
33. Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D. 2009. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 29:14965-14979.
34. Stummer W, Weber K, Tranmer B, Baethmann A, Kempski O. 1994. Reduced mortality and brain damage after locomotor activity in gerbil forebrain ischemia. Stroke 25:1862-1869.
35. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
36. Vogt J, Paul F, Aktas O, Muller-Wielsch K, Dorr J, Dorr S, Bharathi BS, Glumm R, Schmitz C, Steinbusch H, Raine CS, Tsokos M, Nitsch R, Zipp F. 2009. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 66:310-322.
37. White LJ, McCoy SC, Castellano V, Ferguson MA, Hou W, Dressendorfer RH. 2006. Effect of resistance training on risk of coronary artery disease in women with multiple sclerosis. Scand J Clin Lab Invest 66:351-355.
38. Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, Trapp BD. 2002. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 61:23-32.